Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non-Current Liabilities (2016 - 2021)

Protalix BioTherapeutics (PLX) has 8 years of Other Non-Current Liabilities data on record, last reported at $38000.0 in Q2 2021.

  • For Q2 2021, Other Non-Current Liabilities fell 69.35% year-over-year to $38000.0; the TTM value through Jun 2021 reached $38000.0, down 69.35%, while the annual FY2020 figure was $51000.0, 89.98% down from the prior year.
  • Other Non-Current Liabilities reached $38000.0 in Q2 2021 per PLX's latest filing, up from $26000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $6.2 million in Q3 2018 and bottomed at $26000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $2.9 million, with a median of $5.1 million recorded in 2017.
  • Peak YoY movement for Other Non-Current Liabilities: grew 17.44% in 2017, then crashed 99.14% in 2020.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $5.1 million in 2017, then increased by 4.77% to $5.3 million in 2018, then tumbled by 90.38% to $509000.0 in 2019, then crashed by 89.98% to $51000.0 in 2020, then decreased by 25.49% to $38000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $38000.0 in Q2 2021, $26000.0 in Q1 2021, and $51000.0 in Q4 2020.